| |

Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences

ByPsychedelic Spotlight

Similar Posts

  • Interview With Ronan Levy

    Listen, Podcasts

    In this episode of the Psychedelic Spotlight podcast, we catch up with Ronan Levy, Co-Founder and Executive Chairman of Field Trip Health, and discuss the significance behind the company’s recent opening of its psilocybin research and cultivation facility in Jamaica along with the company’s recent listing on the OTCQX.

  • Interview With Carlos Tanner

    Listen, Podcasts

    In this episode, Global Trac Solutions, Inc. CEO, David Flores, has the very distinct pleasure of being joined by Carlos Tanner, founder of the Ayahuasca Foundation in Iquitos, Peru.

  • Psychedelics Aiding Recovery with Arrowyn Ambrose

    Listen, Podcasts

    In this episode, Arrowyn speaks on how psychedelics are integrated into recovery and addiction, how community can profoundly impact those in recovery, and how we can assist those who are in need of psychedelic therapy but may not have access.

  • Speculating on The Future of MindMed [Big News for MMED/MMEDF STOCK]

    Listen, Videos

    Hello back Psychedelic Investors! In this video we are going to be entering the Speculation Zone to discuss the implications of several of MindMed’s most recent moves. Aka, we shall be Speculating on The Future of MindMed [Big News for MMED/MMEDF STOCK].

    Timestamps:
    0:00 – Intro
    2:52 – Speculating on LSD Trials
    7:44 – MindMed’s Partnership Meaning
    13:45 – Nasdaq Uplisting

    This is actually the second video being released today. Earlier we posted a video detailing the three most recent press releases distributed by MindMed, where we explained what each move meant. If you haven’t seen that episode yet and want to get a detailed explanation of each Press Release before watching this video speculating on that information, you should probably do that first!

    Well actually, MindMed has since released another press release since the first video was filmed, on the commencement of their LSD Neutraliser phase 1 clinical trial.
    In our Video on MindMed’s Latest News, we discussed:

    1. How MindMed has started a phase 1 clinical trial studying the effects of mixing LSD and MDMA;
    2. We examined MindMed’s changes in Leadership, where JR Rahn became the sole CEO, and a gentleman by the name of Dr. Glick left the board;
    3. We also talked about MindMed’s new partnership with a company called MindShift Compounds AG, which is developing novel compounds owned exclusively by MMED.

    In this video, we discuss/SPECULATE on all of MindMed’s latest changes and how some of them could potentially influence the MMED/MMEDF stock’s uplisting on NASDAQ.

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video by Pressmaster from Pexels

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMEDF #MindmedStock

  • Interview with James Lanthier, CEO of Mindset Pharma

    Interviews, Listen, Podcasts

    In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.